MERTK and glioblastoma: Su et al. reported that MRX-2843, a MerTK inhibitior, has a therapeutic benefit via promoting GAMs polarization away from immunosuppressive conditions, inhibiting neoangiogenesis in the GBM microenvironment, and inducing tumor cell death [73].